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Abstract: 
Computational assessment of the binding interactions of drugs is an important component of computer-aided drug design paradigms. In this perspective, a set of 30 
1-(substituted phenyl)-3-(naphtha[1, 2-d] thiazol-2-yl) urea/thiourea derivatives showing antiparkinsonian activity were docked into inhibitor binding cavity of 
human adenosine A2A receptor (AA2AR) to understand their mode of binding interactions in silico. Lamarckian genetic algorithm methodology was employed for 
docking simulations using AutoDock 4.2 program. The results signify that the molecular docking approach is reliable and produces a good correlation coefficient 
(r
2 = 0.483) between docking score and antiparkinsonian activity (in terms of % reduction in catalepsy score). Potent antiparkinsonian agents carried methoxy 
group in the phenyl ring, exhibited both hydrophilic and lipophilic interactions with lower energy of binding at the AA2AR. These molecular docking analyses 
should, in our view, contribute for further development of selective AA2AR antagonists for the treatment of Parkinson’s disease. 
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Background: 
Adenosine A2A receptors (AA2AR) are highly distributed in the central nervous 
system and are found in abundance in the basal ganglia, a region of the brain 
associated with motor function [1]. The colocalization of AA2AR and dopamine 
D2 receptors in the striatopallidal neurons provides the anatomical basis for the 
existence of a functional antagonistic interaction between these receptors [2]. 
Stimulation of the dopamine D2 receptors with dopamine or other dopamine D2 
receptor agonists enhances motor activity whereas stimulation of AA2ARs 
reduces this effect [3]. Likewise, AA2AR antagonists may provide a novel 
therapy for the treatment of Parkinson’s disease (PD) with lower risk of 
dyskinesias. In addition, they may exhibit neuroprotective effects [4]. 
Furthermore, AA2AR antagonists were found not only to diminish the 
symptoms of PD but also to potentiate the effect of levodopa [5], so, it may be 
possible to reduce the dose of the dopaminergic drugs and therefore the 
occurrence of side effects. AA2AR antagonists are therefore a promising 
adjunctive to dopamine replacement therapy, and several companies have now 
advanced selective antagonists of this receptor into clinical development [4]. 
Significant progress has been made in computer-aided drug design by 
pharmaceutical companies at different stages of drug discovery such as 
identifying new hits, enhancing molecule binding affinity in hit-to-lead, and 
lead optimization [6]. Moreover, in silico approaches are routinely used in 
modern drug design to help understand drug-receptor interactions. It has been 
shown in the literature that computational techniques can strongly support and 
help the design of novel, more potent inhibitors by revealing the mechanism of 
drug-receptor interactions [7].  
 
Thiazole derivatives have evoked considerable attention in recent years as these 
are endowed with wide range of biological activities as well as drugs of PD [8-
12]. Hoffmann-La Roche discovered benzothiazole derivetives as novel 
scaffold for AA2AR antagonists [13]. Furthermore, certain thiazoles with a urea 
moiety  [14]  have also demonstrated AA2AR antagonistic activities for the 
development of a suitable approach to the treatment of PD that may be the 
starting point for the future drug design. Recently, we have discovered urea 
derivatives of naphtha [1, 2-d] thiazol-2-amine as novel anti-Parkinsonian 
agents that cause neuroprotection against haloperidol-induced oxidative stress 
in mice [10]. These findings have motivated us to reveal their interactions with 
AA2ARs insilico by using AutoDock program and to attest anti-Parkinsonian 
activity associated with them. BIOINFORMATION  open access 
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Materials and Methodology: 
For the present study, crystal structure of human AA2AR with PDB ID: 3EML 
[15] was downloaded from the protein data bank (www.rcsb.org/pdb). For 
docking experiments with AutoDock 4.2, antiparkinsonian molecules reported 
by our group [10] were drawn in ChemBioDraw Ultra 12.0 and converted to 
their three dimensional structures in ChemBio3D Ultra 12.0, energy minimized 
by PM3 method using MOPAC Ultra 2009 program (http://OpenMOPAC.net) 
and saved in pdb format. The prepared ligands were used as input files for 
AutoDock 4.2 in the next step. Lamarckian genetic algorithm method [16] was 
employed for docking simulations. The standard docking procedure was used 
for a rigid protein and a flexible ligand whose torsion angles were identified 
(for 10 independent runs per ligand). A grid of 60, 60, and 60 points in x, y, 
and z directions was built with a grid spacing of 0.375 Å and a distance-
dependent function of the dielectric constant were used for the calculation of 
the energetic map. The default settings were used for all other parameters. At 
the end of docking, the best poses were analyzed for hydrogen bonding/π-π 
interactions and root mean square deviation (RMSD) calculations using 
Discovery Studio Visualizer 2.5 (Accelrys Software Inc.) and Pymol (The 
PyMOL Molecular Graphics System) programs. From the estimated free 
energy of ligand binding (ΔGbinding, kcal/mol), the inhibition constant (Ki) for 
each ligand was calculated (Table 1 see Supplementary material). 
 
 
Figure 1: The native co-crystallized ligand ZM241385 docked with the active 
site of AA2AR.  
 
 
Figure 2: Docked conformation of compound 22 shown as ball and stick in 
grey color. The residues of binding pocket are shown as stick in cyan color. 
Dashed lines in green indicate H-bonds and π-π stacking interactions are shown 
in orange. Bond distances are given in Å. 
 
Results and Discussion: 
Validation of the docking protocol: 
To evaluate the accuracy of AutoDock 4.2 as an appropriate docking tool for 
the present purpose, the co-crystallized ligand (ZM241385) was redocked 
within the inhibitor binding cavity of human AA2AR, and the docked position 
was compared to the crystal structure position by calculating RMSD values 
(0.88 Å, Figure 1). In general, RMSD values smaller than 2.0 Å indicate that 
the docking protocol is capable of accurately predicting the binding orientation 
of the co-crystallized ligand [17]. In this study, RMSD values were within 2.0 
Å, indicating our docking methods are valid for the given structures and 
AutoDock 4.2, therefore deemed reliable for docking of naphtha [1, 2-
d]thiazolyl urea/thiourea derivatives into the inhibitor binding cavity of AA2AR. 
 
Correlation between docking scores and antiparkinsonian activity: 
The results signify that the molecular docking approach is reliable and 
produces a good correlation coefficient (r
2 = 0.483) between docking score and 
antiparkinsonian activity (in terms of % reduction in catalepsy score). Removal 
of 4 compounds (compounds 17, 26, 28 and 30) identified as outliers from the 
docking dataset and yield a better model with correlation coefficient (r
2) of 
0.646 with 26 compounds (Figure 3). Outliers in the molecular docking studies 
are anticipated because, docking calculations simulate the interaction between a 
compound and a protein’s active site and the results are comparable to those of 
biochemical assays/animal experiments; however, it does not take into account, 
the bioavailability, toxicity, and other factors present in the body. 
 
 
Figure 3: A correlation for docking predicted activity and experimental 
antiparkinsonian activity. 
 
Binding interactions of 1-(substituted phenyl)-3-(naphtha [1, 2-d] thiazol-
2-yl) urea/thiourea derivatives with human AA2AR: 
All of the naphtha [1, 2-d] thiazolyl urea/thiourea derivatives were docked into 
the active site of AA2AR (PDB code: 3EML) to study the possible mode of their 
interaction. Docking of these compounds into inhibitor binding cavity of 
AA2AR confirms that these compounds dock in a similar binding modus like 
native co-crystallized ligand, ZM-241385 (Figure 2). Inhibitor binding cavity 
of AA2AR is outlined by residues Ile-66, Ala-81, Leu-85, Phe-168, Glu-169, 
Met-177, Trp-246, Leu-249, His-250, Asn-253, His-264, Leu-267, Met-270, 
Tyr-271, Ser-277 and His-278. Analysis of the receptor/ligand complex models 
generated after successful docking of the urea and thiourea derivatives was 
based on parameters such as: 1) Hydrogen bond interactions; 2) π-π 
stacking/hydrophobic interactions; 3) binding energy; 4) RMSD of active site 
residues; 5) Orientation of the docked compound within the active site. The 
bicyclic triazolotriazine core of ZM241385, native co-crystallized AA2AR 
antagonist, is anchored by an aromatic stacking interaction with Phe-168 [15], 
an aliphatic hydrophobic interaction with Ile 274 [18] and a hydrogen bonding 
interaction with Asn 253 [19]. Likewise, the tricyclic naphthothiazole ring was 
found to interact with aromatic ring of Phe-168 by π-π stacking interactions and 
compound 22 participated in hydrogen bonding with Asn 253. Adjacent to Phe-
168, a polar residue Glu-169 donates a hydrogen bond to oxygen atom of 
methoxy group substituted in phenyl ring of compounds 4, 6, 16, 21 and 22. 
Similarly, exocyclic amino group (N-15 atom) of ZM241385 also participates 
in hydrogen bonding with Glu-169 [15, 20]. As a general rule, in most of the 
potent and fair antiparkinsonian compounds, both hydrogen bond and π-π 
stacking/hydrophobic interactions between the compound and the active site 
residues of the receptor have been found to be responsible for mediating the 
biological activity. In addition to be involved in π-π stacking/hydrophobic 
interactions with most docked compounds, Phe-168 contributes to H-bond 
interactions in compounds 5, 6, 9, 10, 18 and 29. Very potent antiparkinsonian 
agents (compounds 4, 5, 6, 7, 21 and 22) carried methoxy group in the phenyl 
ring and interacted with Phe-168, Glu-169 and His-278 residues for H-bonding. 
However, replacement of methoxy group with phenoxy group (compound 8) 
lost H-bond that resulted in decreased antiparkinsonian activity. Generally, 
compounds substituted with methyl group or halogen in the aromatic ring of 
urea or thiourea derivatives (compounds 3, 8, 9, 10, 15, 16, 19, 20, 23 24, 25, 
26, 27, 31 and 32) demonstrated poor binding energies as well as both BIOINFORMATION  open access 
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hydrophilic and lipophilic interactions. These compounds were also noted to be 
poor antiparkinsonian agents. 
 
Conclusion: 
Molecular docking studies of 1-(substituted phenyl)-3-(naphtha[1,2-d]thiazol-
2-yl)urea/thiourea derivatives with AA2AR exhibited very good binding 
interactions and warrants further studies to confirm their binding with human 
AA2AR for the design and development of potent antagonists as novel 
antiparkinsonian agents. These results clearly indicate that before synthesis and 
biochemical testing of new analogs, one can use molecular docking studies for 
assessment of relative binding affinities with AA2AR for most promising drug 
candidates. 
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Supplementary material: 
 
Table 1: Docking results of 1-(substituted phenyl)-3-(naphtha[1,2-d]thiazol-2-yl)urea/thiourea derivatives with AA2AR. Data of % reduction in catalepsy were 
taken from reference [10]. Compound number is same as given in the literature. 
a)Binding free energy (kcal/mol); 
b)Inhibition constant estimated by docking (in 
nM); 
c)Root mean square deviation (in Å); 
d)Amino acid; 
e)Bond distance (in Å); 
f)No H-bond or pi-interaction. 
Comp.  R  X  % Reduction in catalepsy  ΔGb
a
 
Ki
b RMSD
c Hydrogen  bonds  π-Interactions 
AA
d Dist
e AA
d Dist
e 
3 H  O  44.44 
 
-8.27 863.78  4.29 
 
f - Phe-168  4.14 
     Phe-168  5.25 
     Phe-168  6.43 
4 4-OCH3  O 58.51  -8.81 346.16  3.99  Glu-169 2.16  Phe-168 4.53 
       Tyr-271  1.95  Phe-168  5.26 
5 2-OCH3  O 76.9  -9.00 250.84  4.21  Phe-168 1.97  Phe-168 4.52 
       Tyr-271  1.94  Phe-168  5.24 
6 2,4-OCH3  O 75  -9.25 164.57  4.03  Phe-168 2.15  Phe-168 4.43 
       Glu-169  2.38 
1.96 
Phe-168 5.14 
       Tyr-271 
7 3,4,5-OCH3 O 70.29  -9.07  224.23  3.93  His-278  1.87  Phe-168  4.44 
     Phe-168  5.65 
8 4-Phenoxy  O  55.56  -9.53  102.63  2.52 
f - Phe-168  5.19 
9 2-F  O  29.12  -8.16  1040  4.85  Phe-168  2.02 
2.08 
f - 
       Tyr-271 
10 4-F O  30.3  -8.14  1080  4.83  Phe-168  2.07 
2.05 
f - 
       Tyr-271 
11 2-Br  O  38.74  -8.72  405.86  4.15  Tyr-271  2.18  Phe-168  4.55 
     Phe-168  5.26 
12 4-Br  O  37.76  -8.55  542.28  4.36  Tyr-271  2.11  Phe-168  4.61 
     Phe-168  5.19 
13 2-Cl  O  37.37 
 
-8.54 546.60  4.09 
 
Tyr-271 2.22  Phe-168 4.54 
     Phe-168  5.28 
14 4-Cl  O  38.61  -8.38  721.26  4.34  Tyr-271  2.09  Phe-168  4.60 
     Phe-168  5.19 
15 2-Cl,  5-CF3 O 51.37  -8.94  281.80  4.1  Tyr-271  2.13 
f - 
16 2-NO2 O  72.05  -9.87  58.72  4.69  Glu-169  2.1 
2.1 
f - 
       Glu-169 
17 4-NO2 O  31.28  -8.61  484.40  3.93  Val-84  2.04  Phe-168  5.11 
18 2-CH3  O 47.64  -8.46 626.58  4.01  Phe-168 1.74  Phe-168 4.13 
       Tyr-271  1.89  Phe-168  4.57 
     Phe-168  6.03 
19 4-CH3 O  48.56  -8.65  455.03  4.03 
 
f - Phe-168  4.38 
     Phe-168  5.45 
   -  Phe-168  6.38 
20 H  S  44.63  -8.45  636.96  3.95  Ala-81  2.17  f - 
21 4-OCH3  S 58.05  -9.26 162.54  5.02  Glu-169 2.09  Phe-168 4.27 
       Tyr-271  1.88  Phe-168  3.76 
     Phe-168  3.95 
22 2-OCH3 
 
S 75.46  -9.06 229.22  2.72  Glu-169 1.95  Phe-168 4.01 
       Asn-253  2.39 
1.98 
3.19 
3.02 
Phe-168 5.26 
       Glu-169 
       Glu-169 
       Asn-253 
23 2-F S  38.35  -8.18  1010  1.39 
 
f - Phe-168  3.99 
     Phe-168  4.69 
     Phe-168  5.91 
24 4-F S  34.95 
 
-8.11 1130  4.24 
f - Phe-168  3.91 
     Phe-168  3.81 
     Phe-168  4.45 
25 2-Br  S  30.96  -8.53  562.85  4.05 
 
f - Phe-168  3.68 
     Phe-168  3.79 
     Phe-168  4.49 
26 4-Br  S  35.27  -8.75  388.83  4.22 
f - - - 
27 2-Cl  S  39.14  -8.55  544.16  3.1 
 
f - Phe-168  4.06 
     Phe-168  4.80 BIOINFORMATION  open access 
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     Phe-168  3.88 
28 4-Cl  S  27.88  -8.68  432.38  4.05  Tyr-271  2.22  Phe-168  4.92 
     Phe-168  4.1 
     Phe-168  3.81 
29 2-NO2 S  72.97  -9.61  90.07  2.63  Phe-168  2.15 
1.99 
3.19 
- - 
       Phe-168 
       Ile-66 
30 4-NO2 S  32.13 
 
-8.72 405.62  4.45 
 
His-278 2.05  Phe-168 3.95 
     Phe-168  3.99 
     Phe-168  4.33 
31 2-CH3 S  49.87  -8.66  448.49  4.77 
 
f - Phe-168  4.12 
     Phe-168  4.81 
     Phe-168  6.27 
32 4-CH3 S  47.97  -8.56  529.05  4.30 
f - Phe-168  4.18 
     Phe-168  5.00 
     Phe-168  6.26 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 